<?xml version="1.0" encoding="UTF-8"?>
<p id="para0026">Ribavirin is a guanine analog among approved nucleoside analogs used to treat hepatitis c virus and respiratory syncytial virus infections and has been harnessed to cure patients with SARS 
 <xref rid="bib0085" ref-type="bibr">[85]</xref>. Ribavirin was extensively leveraged for patients with or without concomitant usage of steroids during the SARS outbreak in 2003 
 <xref rid="bib0086" ref-type="bibr">[86]</xref>. When combined with IFN-Î², it can exert the synergistical inhibition effect on SARS-associated CoV replication 
 <italic>in vitro</italic>
 <xref rid="bib0087" ref-type="bibr">[87]</xref>. However, the efficacy and safety of this agent remain uncertain, and it may arouse adverse reactions like anemia in high doses 
 <xref rid="bib0077" ref-type="bibr">[77]</xref>. In COVID-19 therapy, ribavirin was utilized with pegylated interferon for stimulating the innate antiviral reaction at a relatively lower dose to curtail side effects.
</p>
